Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib

Leukemia. 2013 Oct;27(10):2075-7. doi: 10.1038/leu.2013.148. Epub 2013 May 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Disease Models, Animal*
  • Drug Resistance, Neoplasm*
  • Flow Cytometry
  • Humans
  • Mice
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / mortality*
  • Prognosis
  • Pyrazines / therapeutic use*
  • Receptors, CXCR4 / metabolism*
  • Sarcoma, Myeloid / drug therapy
  • Sarcoma, Myeloid / metabolism
  • Sarcoma, Myeloid / mortality*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Receptors, CXCR4
  • Bortezomib